Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Since 1929, ESTEVE has been driven by a clear and powerful purpose: improve people’s lives. Headquartered in Barcelona, we are a global pharmaceutical company with affiliates in Spain, Portugal, Italy, Germany, France, the UK, and the
Senior Manager, Compliance - Field Commercialization (West) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The companys R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic